Celldex Therapeutics (CLDX) takes a hit in the post session after releasing mixed preliminary...

Celldex Therapeutics (CLDX) takes a hit in the post session after releasing mixed preliminary results from randomized Phase 2b tests of CDX-011 antibody drug conjugate in patients with advanced, heavily pretreated breast cancer. Shares -8.5% AH.

From other sites
Comments (4)
  • WavephoreLoser
    , contributor
    Comments (13) | Send Message
    Based on the comments of the lead investigator, Dr. Vahdat, it is clear to me that this "setback" is exactly what Hepatitis-C company Inhibitex went through after a successful Phase II study was labeled "mixed". INHX dropped from about 3 to the low 2's. A few months later it was sold for $26/share. I unfortunately chickened out despite my appreciating that the results had been unfairly viewed as negative. I see the same thing here, and I do not intend to chicken out this time. This drug works; it's not just promising at this point. Phase III will look much better, just like Inhibitex's Phase III because Phase II has provided a clear direction and convincing proof of efficiacy.
    23 May 2012, 05:36 PM Reply Like
  • ajbrzoz
    , contributor
    Comments (61) | Send Message
    The lead investigator from the Celldex CDX-011 Phase 2B trial feels that the results are very promising:


    "The correlation with GPNMB expression rates and clinical responses in this study confirms the role of GPNMB as a potentially new and important cancer target," said Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study. "These results are promising in this heavily pretreated patient population for which there are few treatment options left. With continued positive results, CDX-011 has the potential to offer a possible new and important targeted therapy."


    The AH movement in the pps is a result of the price being driven down so that the big boys can get in at a lower price, because the trial results are anything but "mixed".
    23 May 2012, 06:30 PM Reply Like
  • Richrd_CC
    , contributor
    Comment (1) | Send Message
    The results were not mixed at all. The results are very good and surpassed the benchmark of what would be considered good results. Celldex is ready to sit down with the FDA to discuss the next step so that it can reach fast-track approval in a more timely manner.


    CDX-011 is definitely a winner and Celldex Therapeutics will be moving higher because of this and because of other drug products in their pipeline. Partnership(s) and potential buyout within a short term period of time is very possible.
    23 May 2012, 11:03 PM Reply Like
  • slowtime
    , contributor
    Comments (32) | Send Message
    Well done CLDX!!! Now I forgive you for screwing up the attendance form for ASCO-12. Or was it done on purpose? A Machiavellian thought.
    After the misguided shorts started selling in AH from 5.12 to 3.40, I bought at really fantastic price, at 3.57 3.60 3.80 3.87, enough to give these all back to the shorts at 10, 12, 15.
    24 May 2012, 08:22 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs